CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Enoxaparindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02706249
NCT02706249Phase 2Completed
CompareCT.gov

A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

Dana-Farber Cancer Institute·interventional·Posted Mar 11, 2016·Updated Jul 8, 2021

In Brief

A Phase 2 clinical trial evaluating Enoxaparin for Venous Thormboembolism. Completed, enrolled 50 participants across 2 sites.

Detailed Summary

Hospitalized patients with histologically or cytologically confirmed diagnosis of solid tumor malignancy, lymphoma, or multiple myeloma and who are at high risk for a venous thromboembolism will be randomized to standard dose versus intermediate dose enoxaparin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thormboembolism
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 11, 2016
Enrollment StartApr 1, 2016
Primary CompletionDec 7, 2020
Study CompletionJun 7, 2021
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 10.3 years ago

Interventions

Enoxaparindrug